Production (Stage)
aTyr Pharma, Inc.
ATYR
$3.88
$0.1253.33%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | 0.58% | 13.28% | -5.84% | -5.26% | -4.95% |
Total Depreciation and Amortization | 38,400.00% | -100.26% | 1.31% | -50.26% | 89.19% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 202.78% | 53.19% | 1,862.50% | 88.06% | 70.61% |
Change in Net Operating Assets | -197.35% | -54.65% | 179.06% | 40.49% | -315.74% |
Cash from Operations | -17.42% | 0.20% | 35.65% | 8.63% | -102.31% |
Capital Expenditure | -- | -66.67% | -87.50% | 52.94% | 0.00% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 27.15% | -133.78% | 166.64% | 603.06% | -107.51% |
Cash from Investing | 27.36% | -133.91% | 166.74% | 596.17% | -107.61% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -2.34% | -2.40% | -1.63% | -1.65% | -5.22% |
Issuance of Common Stock | -1.10% | 94,735.00% | -99.85% | 72.25% | 27.68% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -1.12% | 18,041.90% | -100.78% | 73.35% | 28.11% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -220.63% | -108.07% | 1,558.88% | 97.99% | -225.14% |